Megan E. Melody

Hematology

3140 S Falkenburg Rd Ste 301
Riverview, FL 33578

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 27 publications

Prognostic factors for early mortality following allogeneic hematopoietic cell transplantation in hematologic malignancies.

Prognostic factors for early mortality following allogeneic hematopoietic cell transplantation in hematologic malignancies.

Journal: Transplantation and cellular therapy

Published: May 26, 2026

Prognostic Factors for Early Mortality Following Allogeneic Hematopoietic Cell Transplantation in Hematologic Malignancies.

Prognostic Factors for Early Mortality Following Allogeneic Hematopoietic Cell Transplantation in Hematologic Malignancies.

Journal: Transplantation and cellular therapy

Published: May 26, 2026

Assessment of Fellowship Didactic Curricula in Hematology/Oncology: Cross-Sectional Findings From the PODCAST-HOF Trial.

Assessment of Fellowship Didactic Curricula in Hematology/Oncology: Cross-Sectional Findings From the PODCAST-HOF Trial.

Journal: Journal of cancer education : the official journal of the American Association for Cancer Education

Published: October 31, 2025

Educational Impact of a Podcast Curriculum for Hematology/Oncology Fellows: Final Results of the Multicenter Cluster Randomized PODCAST-HOF Trial.

Educational Impact of a Podcast Curriculum for Hematology/Oncology Fellows: Final Results of the Multicenter Cluster Randomized PODCAST-HOF Trial.

Journal: JCO oncology practice

Published: May 31, 2025

Outcomes for CART as 2L vs 3L vs 4L or beyond in aggressive B-cell lymphoma: real-world evidence from the ABC Consortium.

Outcomes for CART as 2L vs 3L vs 4L or beyond in aggressive B-cell lymphoma: real-world evidence from the ABC Consortium.

Journal: Blood advances

Published: May 09, 2025

Outcomes of bispecific antibodies after CAR T-cell failure for large B-cell lymphoma: results from the ABC consortium.

Outcomes of bispecific antibodies after CAR T-cell failure for large B-cell lymphoma: results from the ABC consortium.

Journal: Blood advances

Published: April 24, 2025

Case Report: Severe brigatinib-induced pneumonitis in a patient with EML4-ALK+ metastatic non-small cell lung adenocarcinoma.

Case Report: Severe brigatinib-induced pneumonitis in a patient with EML4-ALK+ metastatic non-small cell lung adenocarcinoma.

Journal: Frontiers in oncology

Published: February 07, 2025

Sequencing of cellular therapy and bispecific antibodies for the management of diffuse large B-cell lymphoma.

Sequencing of cellular therapy and bispecific antibodies for the management of diffuse large B-cell lymphoma.

Journal: Haematologica

Published: April 16, 2024

Dosing of 7 + 3 induction chemotherapy in a patient with acute myeloid leukemia (AML) and morbid obesity.

Dosing of 7 + 3 induction chemotherapy in a patient with acute myeloid leukemia (AML) and morbid obesity.

Journal: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners

Published: March 21, 2024

Subsequent malignant neoplasms in patients previously treated with anti-CD19 CAR T-cell therapy.

Subsequent malignant neoplasms in patients previously treated with anti-CD19 CAR T-cell therapy.

Journal: Blood advances

Published: January 04, 2024

Incidence of thrombosis in relapsed/refractory B-cell lymphoma treated with axicabtagene ciloleucel: Mayo Clinic experience.

Incidence of thrombosis in relapsed/refractory B-cell lymphoma treated with axicabtagene ciloleucel: Mayo Clinic experience.

Journal: Leukemia & lymphoma

Published: February 03, 2022

Treatment outcomes for patients with myelodysplastic syndrome/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis.

Treatment outcomes for patients with myelodysplastic syndrome/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis.

Journal: Leukemia & lymphoma

Published: August 27, 2021

Showing 1-12 of 27

Last Updated: 09/26/2026